ClinicalTrials.gg
CompletedNCT06855056PROSPECTUpdated Sep 10, 2026

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

An observational study in Liver Cirrhosis and Decompensated Cirrhosis of Liver, sponsored by European Foundation for Study of Chronic Liver Failure. Completed at 9 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by European Foundation for Study of Chronic Liver Failure · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
189
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Liver Cirrhosis with a site in Spain — 16 open to participants now, 20 under way, 3 of them phase 3. Liver Cirrhosis · Spain.

Enrollment
17th of 26
189 · median 334
Started
2025
with 1 other
Observational
26 of 76
8 open now
Registered
73rd of 76
by date
Lead sponsor
3 of 76
European Foundation for Study of Chronic Liver Failure

Among the 76 studies in Liver Cirrhosis with a site in Spain, this one is the 17th largest by enrollment of the 26 observational ones that give a count, is one of 2 that started in 2025, is one of 26 observational ones, and was the 73rd registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

16 of the 76 studies in Liver Cirrhosis with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Liver Cirrhosis with a site in Spain, or all of them as a file.
02

Study summary

The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease

Read the detailed description

The PROSPECT study is part of the larger EU H2020 DECISION project, which aims to analyze and clarify the pathophysiological mechanisms of decompensated cirrhosis at the systemic level and its transition to ACLF, with the goal of significantly reducing mortality through therapies tailored to the specific needs of individual patients or patient groups.

As planned in the DECISION project, the biological samples of three large cohorts of patients with cirrhosis admitted to hospital for acute decompensation (AD) without ACLF, deriving from the EF-CLIF-promoted observational studies CANONIC and PREDICT (Europe) and ACLARA (South America) were analyzed to measure lipidomics, epigenomics, whole-blood transcriptomics, micro-RNA, serum metabolomics, plasma cytokines, and plasma extracellular vesicles.

Both system medicine approaches and more traditional methods of analysis have been applied to analyze and interpret the results. The analyses are still ongoing due to the very high number of variables and the complexity of associating -omics to clinical data, yet, some of these analyses have already generated solid data allowing the identification of novel biomarkers which can be further tested.

In the PROSPECT study, patients hospitalized for acute decompensation of liver cirrhosis, who meet the inclusion and exclusion criteria, will be enrolled after providing signed informed consent. Participants will be screened and included in the study within 48 hours prior to the expected discharge from the hospital. The study will last 180 days and will include an initial visit during which clinical parameters and additional blood samples will be collected, followed by two follow-up visits - which can also be conducted by phone - during which only clinical information will be gathered. Samples will be analyzed to determine the biomarkers selected within the DECISION project and parameters related to the following pathophysiological mechanisms:

  • systemic inflammation
  • blood and microRNA transcriptome
  • the metabolomic landscape
  • albumin structure and function
  • coagulation assays
  • extracellular vesicles
  • endothelial function
03

Conditions studied

  • Liver Cirrhosis
  • Decompensated Cirrhosis of Liver

Keywords

  • Decompensated Liver Cirrhosis
  • Acute on Chronic Liver Failure (ACLF)
  • Liver Diseases
  • Liver Cirrhosis
  • Biomarkers
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients eligible for this study will be patients with decompensated cirrhosis expected to be discharged from the hospital within 48 hours after an index admission for AD according to the EASL-CLIF criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 80 years.
  2. Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive- related gastrointestinal bleeding, bacterial infection, or any combination of these), including those who presented ACLF during hospitalization.
  3. Recovery from AD and expected to be discharged within the next 48 hours.

Exclusion criteria

Exclusion Criteria:

  1. Admission for planned diagnostic or therapeutic procedures
  2. Active (except for hepatocellular carcinoma within the Milan criteria or nonmelanocytic skin cancer)
  3. Antiviral treatment for , B and delta initiated in the last 6 months or planned to be initiated in the following 6 months.
  4. positive (except undergoing treatment and who do not exhibit clinical manifestations of AIDS).
  5. Ongoing alcohol use disorder with an expected low adherence to prescriptions as judged by physician
  6. Previous liver or other organ transplantation
  7. Patients with TIPS or other surgical porto-caval shunts
  8. Chronic organic renal failure stage IV and V or estimated \<20 ml/min according to the MDRD equations
  9. Chronic heart failure class III or IV
  10. Pulmonary disease GOLD III or IV
  11. Patients with a history of significant extrahepatic disease with \<6 months
  12. Severe psychiatric disorders
  13. Pregnancy and breast-feeding
  14. Expected low adherence to study protocol as judged by physician
  15. Patients who cannot provide written or refuse to participate
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
189 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with Decompensated Liver Cirrhosis

    Patients eligible for this study will be patients with decompensated cirrhosis expected to be discharged from the hospital within 48 hours after an index admission for AD according to the EASL-CLIF criteria

06

What researchers measure

Primary outcomes

  1. To test the prognostic accuracy of novel biomarkers identified within the DECISION project.

    The primary objective will be evaluated assessing the following end-point: ● Survival at 3 months

    Time frame: Until September 30th 2025

Secondary outcomes

  1. To characterize the clinical and biological features at the time of discharge predicting the 6-month outcome and the different trajectories of patients surviving a hospitalization for AD complicated or not by ACLF.

    Secondary objectives will be evaluated assessing the following end-points: * Survival at 6 months * Incidence of emergent re-admissions to hospital at 3 months due to liver related causes * Incidence of emergent re-admissions to hospital at 6 months due to liver related causes * Incidence of emergent re-admissions to hospital at 3 months due to non liver related causes * Incidence of emergent re-admissions to hospital at 6 months due to non liver related causes * Incidence of ACLF at 3 months * Incidence of ACLF at 6 months * Incidence of TIPS insertion at 3 months * Incidence of TIPS insertion at 6 months

    Time frame: Until September 30th 2025

07

Study locations

9 sites
  • Hospital Beaujon
    Clichy, 92110, France
  • University Hospital, Aachen
    Aachen, 52074, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico di S.Orsola
    Bologna, Italia 40138, Italy
  • A.O.U. Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Hospital Universitari Vall d'Hebron Research Institute
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jul 2026, 16 months.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 16 months is below that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Mar 3, 2025
StartActual
Mar 1, 2025
Primary completionActual
Jul 1, 2026
CompletionActual
Sep 1, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06855056
Lead sponsor
European Foundation for Study of Chronic Liver Failure
Collaborators
Universität Münster, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Hospital Universitari Vall d'Hebron Research Institute, Hospital Clinic of Barcelona, Hospital Universitario Ramon y Cajal, Beaujon Hospital, University Hospital, Aachen, A.O.U. Città della Salute e della Scienza
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Mar 1, 2025
Primary completion
Jul 1, 2026
Completion
Sep 1, 2026
Last update
Sep 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion